In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series A generates impressive $104mm for Adaptimmune

Executive Summary

Adaptimmune Ltd. (developing T-cell therapies for cancer and infectious diseases) closed an oversubscribed Series A financing of $104mm. New Enterprise Associates led and was joined by other first-time backers OrbiMed Advisors, Wellington Management Co., Fidelity Biosciences, Foresite Capital Management, Ridgeback Capital Management, Novo AS, QVT, Rock Springs Capital, venBio Select, and Merlin Nexus, along with returning investors including the University of Oxford and others.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies